# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Phillis Wheatley (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN015-SYN
- Date: 2026-02-23
- Fictional facility: St. Posthumous Health Center
- Fictional author: Abena Hartley-Okonkwo, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Diagnosis visit: lung function and FeNO results with the pulmonology consultation. **S**

## History of present illness

Miss Wheatley returns two weeks after her first visit. This morning she had spirometry before and after albuterol and FeNO in the pulmonary function laboratory, and she then saw Dr. Fairbanks-Mensah. Her symptoms are unchanged in the cold weather: wheeze and cough on three or four days a week, waking with a tight chest about twice a month, and breathlessness climbing hills in the wind. The tuberculosis blood test and urine pregnancy test from the first visit were negative. She wants to understand exactly what the tests show and asks whether she will be well enough to travel by sea later in the spring. She came alone and was seen alone. **S**

| Element | Detail |
|---|---|
| Tests this morning | Spirometry with bronchodilator response, and FeNO |
| Results from the first visit | Interferon-gamma release assay negative; urine pregnancy test negative; chest X-ray clear; blood eosinophils 0.38 |
| Her question | Is it asthma, and can she travel by sea in the spring? |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Wheeze and cough three or four days a week; night waking about twice a month; breathless on hills in cold air |
| Constitutional | Negative | No fever, night sweats or weight loss; weight 45.8 kg |
| Ears, nose, mouth, and throat | Negative | No nasal blockage or hoarseness |
| Psychiatric | Negative | Calm; keen to understand her results |

4 systems reviewed. **S**

## Current medications

- Budesonide-formoterol 160/4.5 mcg inhaler as needed only (GINA track 1, step 2, anti-inflammatory reliever): one inhalation whenever needed for symptoms or before exercise in the cold, no more than 12 inhalations a day **S**

## Allergies

- No known allergy **S**

## Objective

BP 106/66 mmHg; pulse 82 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 45.8 kg; BMI 19.8 kg/m². All vital signs are synthetic.

FEV1 before bronchodilator: 2.24 L; FEV1 after bronchodilator: 2.57 L; FEV1 percent predicted before bronchodilator: 83%; FEV1/FVC before bronchodilator: 0.72 (low); FEV1/FVC after bronchodilator: 0.8; FeNO: 38 [ppb] (high); Total IgE: 165 [IU]/mL (high); Asthma Control Test: 16. All results are synthetic.

## Change since baseline

- Asthma Control Test: 15 at baseline, 16 at this visit **S**

## Immunizations given today

- Influenza vaccine, this season **S**
- COVID-19 mRNA vaccine, this season's formula **S**
- Pneumococcal conjugate vaccine PCV20 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Slight, composed and attentive; speaks in full sentences; weight 45.8 kg; oxygen saturation 98 percent |
| Respiratory | Faint expiratory wheeze on forced expiration; no crackles |
| Cardiovascular | Regular rhythm; no murmur |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Asthma, confirmed, mild persistent** (J45.30). Asthma confirmed: FEV1/FVC 0.72 is below the lower limit of normal for her age and rises to 0.80 after albuterol, with a 330 mL (15 percent) rise in FEV1; FeNO 38 ppb and blood eosinophils of 0.38 point to type 2 inflammation, and she is sensitized to house dust mite. Tuberculosis and other chest disease are excluded by a negative interferon-gamma release assay and a clear chest X-ray. Read with race-neutral equations, her FEV1 is 83 percent of predicted. Symptoms on several days a week but fewer than daily, with waking twice a month, fit GINA step 2. **S**
   - Budesonide-formoterol 160/4.5 mcg, one inhalation as needed for symptoms and before going out in the cold, up to 12 a day (GINA track 1, step 2); no albuterol-only reliever.
   - Inhaler technique taught with a spacer and checked today.
   - Written asthma action plan; peak flow meter and a two-week diary to set her personal best.
   - Influenza, COVID-19 and pneumococcal (PCV20) vaccines today.
   - Triggers: open a window and use a fan when cooking, keep away from fireplace smoke, a scarf over the mouth in cold wind, mite-proof bedding covers.
2. **Wheeze, cough and breathlessness** (R06.2). Explained by the diagnosis made today; superseded. **S**
   - Problem resolved.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Spirometry with bronchodilator response, read with race-neutral equations | At diagnosis, before starting controller therapy | Completed today | FEV1 2.24 L (83 percent) to 2.57 L (+330 mL, +15 percent); FEV1/FVC 0.72 to 0.80 |
| Imaging | FeNO | When the diagnosis is uncertain, and to monitor response (NAEPP, conditional) | Completed today | 38 ppb, intermediate |
| Laboratory | Blood eosinophils and total and specific IgE (phenotyping) | At diagnosis | Completed today | Eosinophils 0.38 two weeks ago; total IgE 165; house dust mite specific IgE positive; cat and mold negative |
| Laboratory | Exclusion of tuberculosis and other chest disease | At diagnosis, for a person born where tuberculosis is common | Up to date | Interferon-gamma release assay negative and chest X-ray clear at the first visit |
| Survey | Asthma Control Test, symptoms, night waking and reliever use | Every visit | Completed today | Asthma Control Test 16; symptoms three or four days a week; night waking twice a month |
| Examination | Inhaler technique with her own inhaler, and adherence | Every visit; before any step-up | Completed today | Taught today with her new inhaler and a spacer; demonstrated correctly |
| Self-management | Written asthma action plan | Every visit and after every exacerbation | Completed today | Written plan with peak flow zones given |
| Self-management | Exacerbation history (oral corticosteroid courses, emergency visits, admissions) | Every visit | Completed today | No oral corticosteroid course, emergency visit or admission ever |
| Self-management | Step-up or step-down assessment (GINA track 1) | Every visit | Completed today | Starting at step 2: as-needed low-dose budesonide-formoterol |
| Self-management | Triggers, exposures and smoking or vaping | Every visit | Completed today | Never smoked or vaped; cold air, cooking and fireplace smoke, colds; house dust mite sensitization |
| Examination | Comorbidities: rhinitis, reflux, mood, anxiety | At diagnosis and yearly | Completed today | No rhinitis or reflux symptoms; PHQ-2 1 at the first visit |
| Self-management | Vaccinations | Yearly | Completed today | Influenza, COVID-19 and PCV20 today |
| Referral | Biologic assessment | When asthma is severe or uncontrolled despite optimized step 4 to 5 treatment | Not indicated | Mild asthma; treatment has only now started |
| Self-management | Equity: race-neutral interpretation and plain explanation | Every test | Completed today | Read with GLI Global equations; results explained to her in plain words, with a printed copy for her |
| Self-management | Private conversation: consent, safety and exploitation, and her own decisions | Every visit | Completed today | Seen alone; she consented to each test and treatment; results kept to her own contact details |

## Goal progress

- A confirmed diagnosis within two weeks: spirometry with bronchodilator response and FeNO, with tuberculosis excluded. Outcome by 2026-02-23: Asthma confirmed by a 330 mL (15 percent) bronchodilator response and FeNO 38 ppb; tuberculosis test negative and chest X-ray clear, two weeks after the first visit. **S**
- Asthma Control Test 20 or more with no night waking. In progress; target 2026-04-06. **S**
- Correct inhaler technique and a written action plan she can use at home and at sea. In progress; target 2026-04-06. **S**
- Well enough to make the sea journey and spend the summer away. In progress; target 2026-09-21. **S**
- No exacerbation needing an oral corticosteroid. In progress; target 2026-10-26. **S**
- Hepatitis B and HPV vaccination complete. In progress; target 2027-01-25. **S**

## Medication changes

- Started: Budesonide-formoterol 160/4.5 mcg inhaler as needed only (GINA track 1, step 2, anti-inflammatory reliever): one inhalation whenever needed for symptoms or before exercise in the cold, no more than 12 inhalations a day **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, asthma monograph (2026), Aether Forge
- Global Strategy for Asthma Management and Prevention, 2025 update (2025), Global Initiative for Asthma
- 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020), National Heart, Lung, and Blood Institute (J Allergy Clin Immunol 2020;146(6):1217-1270)
- Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023), American Thoracic Society
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention

## Follow-up

- Six-week review. Follow the action plan: more reliever inhalations and a call to the clinic in the yellow zone; emergency care in the red zone. **S**
- Next scheduled visit 2026-04-06: six-week asthma review: control, technique, personal best peak flow, triggers, and planning for a long sea journey and a summer away. **S**
